✦ LIBER ✦

A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors

✍ Scribed by Yelena Y. Janjigian; Wooin Lee; Mark G. Kris; Vincent A. Miller; Lee M. Krug; Christopher G. Azzoli; Emir Senturk; M. Wade Calcutt; Naiyer A. Rizvi

Publisher: Springer
Year: 2009
Tongue: English
Weight: 254 KB
Volume: 65
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-009-1088-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I trial of perillyl alcohol in p

A phase I trial of perillyl alcohol in patients with advanced solid tumors

✍ Christopher G. Azzoli; Vincent A. Miller; Kenneth K. Ng; Lee M. Krug; David R. S 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 232 KB

Phase I studies of porfiromycin (NSC—564

Phase I studies of porfiromycin (NSC—56410) in solid tumors

✍ Dr. Theodor B. Grage; Arthur J. Weiss; William Wilson; Vernon Reynolds 📂 Article 📅 1975 🏛 John Wiley and Sons 🌐 English ⚖ 354 KB

A phase i study of emetine hydrochloride

A phase i study of emetine hydrochloride (nsc 33669) in solid tumors

✍ Michael J. Mastrangelo; Theodor B. Grage; Robert E. Bellet; Arthur J. Weiss 📂 Article 📅 1973 🏛 John Wiley and Sons 🌐 English ⚖ 445 KB 👁 2 views

Phase I trial of oral MAC-321 in subject

Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors

✍ A. C. Lockhart; R. Bukowski; M. L. Rothenberg; K. K. Wang; W. Cooper; J. Grover; 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 212 KB

A phase I trial of gemcitabine in combin

A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors

✍ William Schelman; Sherry Morgan-Meadows; Howard Bailey; Kyle Holen; James P. Tho 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 325 KB

Phase I clinical trial and pharmacokinet

Phase I clinical trial and pharmacokinetics of weekly ICRF-187 (NSC 169780) infusion in patients with solid tumors

✍ Charles L. Vogel; Elizabeth Gorowski; Enrique Davila; Mario Eisenberger; James K 📂 Article 📅 1987 🏛 Springer US 🌐 English ⚖ 823 KB

ICRF-187 was given to 62 evaluable patients with advanced solid tumors in a Phase I clinical trial. Weekly infusions were given in dosages ranging from 0.85 g/m2 to 7.42 g/m2 for a total of four weeks with a two week rest period between courses. Dose-limiting hematological toxicity was seen in heavi